{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Snyman J"],"funding":["Sub-Saharan African Network for TB/HIV Research Excellence, a DELTAS","Africa Health Research Institute","South African Department of Science and Innovation through the National Research Foundation (South African Research Chairs Initiative","Bill and Melinda Gates Foundation","Wellcome Trust","Africa Initiative"],"pagination":["e249-e256"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8522359"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["75(1)"],"pubmed_abstract":["<h4>Background</h4>There is limited understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis in African populations with a high burden of infectious disease comorbidities such as human immunodeficiency virus (HIV). The kinetics, magnitude, and duration of virus-specific antibodies and B-cell responses in people living with HIV (PLWH) in sub-Saharan Africa have not been fully characterized.<h4>Methods</h4>We longitudinally followed SARS-CoV-2-infected individuals in Durban, KwaZulu-Natal, South Africa, and characterized SARS-CoV-2 receptor-binding domain-specific immunoglobulin (Ig) M, IgG, and IgA weekly for 1 month and at 3 months post-diagnosis. Thirty of 72 (41.7%) were PLWH, 25/30 (83%) of whom were on antiretroviral therapy (ART) with full HIV suppres"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave."],"pmcid":["PMC8522359"],"funding_grant_id":["INV-018944","64809","201433/Z/16/Z","DEL-15–006","107752/Z/15/Z"],"pubmed_authors":["Naidoo K","Ndung'u T","Harling G","Smit T","Goulder P","Madansein R","COVID-19 Mechanisms and Multi-omics at the Intersection of TB and HIV in KwaZulu-Natal (COMMIT-KZN Team)","Wong E","Krause R","Herbst K","Sigal A","Ganga Y","Moshabela M","Leslie A","Jeena P","Nyamande K","Steyn A","Mazibuko M","Klein N","Dullabh KJ","Mthabela N","Patel V","Archary M","Khoza T","Harrichandparsad R","Snyman J","Reddy T","Kloverpris H","Hwa SH","Karim F","Marakalala M","Ndhlovu Z","Muema D","Padayatchi N"],"additional_accession":[]},"is_claimable":false,"name":"Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave.","description":"<h4>Background</h4>There is limited understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis in African populations with a high burden of infectious disease comorbidities such as human immunodeficiency virus (HIV). The kinetics, magnitude, and duration of virus-specific antibodies and B-cell responses in people living with HIV (PLWH) in sub-Saharan Africa have not been fully characterized.<h4>Methods</h4>We longitudinally followed SARS-CoV-2-infected individuals in Durban, KwaZulu-Natal, South Africa, and characterized SARS-CoV-2 receptor-binding domain-specific immunoglobulin (Ig) M, IgG, and IgA weekly for 1 month and at 3 months post-diagnosis. Thirty of 72 (41.7%) were PLWH, 25/30 (83%) of whom were on antiretroviral therapy (ART) with full HIV suppres","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-09T09:34:45.676Z","creation":"2024-12-03T19:27:36.388Z"},"accession":"S-EPMC8522359","cross_references":{"pubmed":["34472583"],"doi":["10.1093/cid/ciab758"]}}